By Abigail Summerville
NEW YORK, June 11 (Reuters) - O Positiv Health is exploring a sale that could value the women's health supplements company at around $1 billion, according to three people familiar with the matter.
The founder-owned business is working with investment bank Jefferies on the sale effort, said the sources, who added that O Positiv is projecting $275 million of revenue this year after generating around $225 million in 2024.
The sources cautioned that no deal was guaranteed, and spoke on condition of anonymity to discuss private information.
Jefferies declined to comment. O Positiv did not respond to a comment request.
Siblings Bobby and Brianna Bitton launched O Positiv in 2018. The company makes vitamins and probiotics that address a variety of health concerns, from PMS and menopause symptoms to vaginal and gut health.
The products are sold on the company's website, as well as through retailers including Walmart WMT.N, Target TGT.N and Amazon AMZN.O.
Consumer health companies and private equity firms alike have put more emphasis on investing in the women's health space in recent years, which has created a significant pool of buyers for brands founded by entrepreneurs.
Such deals include Pharmavite buying Bonafide in November 2023 and L Catterton, in partnership with actress Naomi Watts, acquiring Stripes Beauty last year.
(Reporting by Abigail Summerville in New York; Editing by David French and Matthew Lewis)
((abigail.summerville@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.